Tune the channel: TRPM8 targeting in prostate cancer.
TRPM8
cancer translational research
precision oncology
prostate cancer
Journal
Oncoscience
ISSN: 2331-4737
Titre abrégé: Oncoscience
Pays: United States
ID NLM: 101636666
Informations de publication
Date de publication:
2021
2021
Historique:
received:
09
06
2021
accepted:
06
09
2021
entrez:
13
9
2021
pubmed:
14
9
2021
medline:
14
9
2021
Statut:
epublish
Résumé
The therapeutic landscape of cancer treatments is quickly evolving thanks to the advent of precision oncology. Discovery of novel druggable targets and more reliable biomarkers is a primary objective towards personalized strategies of cancer treatment. Highly expressed in the prostate epithelium within the human body, Transient Receptor Potential subfamily M member 8 (TRPM8) levels rise in primary and hormone naïve metastatic prostate cancer (PCa) lesions, which makes this channel an interesting prototype of molecular target. Recently, by combining a multidisciplinary approach to an
Identifiants
pubmed: 34514058
doi: 10.18632/oncoscience.543
pii: 543
pmc: PMC8428510
doi:
Types de publication
Journal Article
Langues
eng
Pagination
97-100Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST Authors have no conflicts of interest to declare.
Références
Cell. 2002 Mar 8;108(5):705-15
pubmed: 11893340
Nat Genet. 2009 May;41(5):619-24
pubmed: 19396168
Cell Calcium. 2007 Dec;42(6):618-28
pubmed: 17517434
J Pathol. 2008 Dec;216(4):387-93
pubmed: 18853439
Biomaterials. 2014 Oct;35(30):8635-48
pubmed: 25028336
JCO Glob Oncol. 2021 Apr;7:530-537
pubmed: 33856890
Ann Oncol. 2015 Jun;26(6):1041-1042
pubmed: 25862438
Eur Urol. 2020 May;77(5):614-627
pubmed: 32146018
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
J Clin Invest. 2007 Jun;117(6):1647-57
pubmed: 17510704
Mol Membr Biol. 2010 Oct;27(7):286-98
pubmed: 21028937
Nat Genet. 2009 May;41(5):524-6
pubmed: 19396167
Pflugers Arch. 2018 Oct;470(10):1419-1429
pubmed: 29926226
Int J Oncol. 2003 Jul;23(1):221-8
pubmed: 12792797
Cell Death Dis. 2020 Dec 7;11(12):1039
pubmed: 33288740
Cancer Res. 2001 May 1;61(9):3760-9
pubmed: 11325849
Cancer Res. 2003 Jul 15;63(14):4196-203
pubmed: 12874026
Pharmaceuticals (Basel). 2016 Jul 09;9(3):
pubmed: 27409624
Curr Pharm Biotechnol. 2011 Jan 1;12(1):68-77
pubmed: 20932257
Pak J Pharm Sci. 2008 Oct;21(4):370-8
pubmed: 18930858
Int J Mol Sci. 2019 May 28;20(11):
pubmed: 31141957
Signal Transduct Target Ther. 2020 Mar 20;5(1):22
pubmed: 32296018
Sci Rep. 2019 May 28;9(1):7926
pubmed: 31138874
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Pflugers Arch. 2018 May;470(5):761-777
pubmed: 29700598
N Engl J Med. 2016 Oct 13;375(15):1415-1424
pubmed: 27626136
Eur Urol. 2012 Mar;61(3):452-4
pubmed: 22176781
Pathologica. 2021 Apr;113(2):95-101
pubmed: 33955429
J Urol. 2004 Sep;172(3):1175-8
pubmed: 15311065
Eur Urol. 2021 Jul;80(1):82-94
pubmed: 33840558
J Clin Oncol. 2019 May 10;37(14):1159-1168
pubmed: 30860948
Front Pharmacol. 2019 Mar 12;10:230
pubmed: 30930778
Front Oncol. 2019 Nov 26;9:1263
pubmed: 31850193
Nature. 2002 Mar 7;416(6876):52-8
pubmed: 11882888
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1339-1350
pubmed: 33094433
Physiol Rev. 2018 Apr 1;98(2):559-621
pubmed: 29412049
Cell. 2015 Nov 5;163(4):1011-25
pubmed: 26544944
Neoplasia. 2008 Feb;10(2):177-88
pubmed: 18283340